Cargando…

Anti-platelet therapy: ADP receptor antagonists

The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijeyeratne, Yanushi Dullewe, Heptinstall, Stan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187865/
https://www.ncbi.nlm.nih.gov/pubmed/21518389
http://dx.doi.org/10.1111/j.1365-2125.2011.03999.x
_version_ 1782213367831724032
author Wijeyeratne, Yanushi Dullewe
Heptinstall, Stan
author_facet Wijeyeratne, Yanushi Dullewe
Heptinstall, Stan
author_sort Wijeyeratne, Yanushi Dullewe
collection PubMed
description The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
format Online
Article
Text
id pubmed-3187865
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Science Inc
record_format MEDLINE/PubMed
spelling pubmed-31878652011-10-12 Anti-platelet therapy: ADP receptor antagonists Wijeyeratne, Yanushi Dullewe Heptinstall, Stan Br J Clin Pharmacol Haemostasis Themed Issue The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function. Blackwell Science Inc 2011-10 /pmc/articles/PMC3187865/ /pubmed/21518389 http://dx.doi.org/10.1111/j.1365-2125.2011.03999.x Text en Copyright © 2011 The British Pharmacological Society
spellingShingle Haemostasis Themed Issue
Wijeyeratne, Yanushi Dullewe
Heptinstall, Stan
Anti-platelet therapy: ADP receptor antagonists
title Anti-platelet therapy: ADP receptor antagonists
title_full Anti-platelet therapy: ADP receptor antagonists
title_fullStr Anti-platelet therapy: ADP receptor antagonists
title_full_unstemmed Anti-platelet therapy: ADP receptor antagonists
title_short Anti-platelet therapy: ADP receptor antagonists
title_sort anti-platelet therapy: adp receptor antagonists
topic Haemostasis Themed Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187865/
https://www.ncbi.nlm.nih.gov/pubmed/21518389
http://dx.doi.org/10.1111/j.1365-2125.2011.03999.x
work_keys_str_mv AT wijeyeratneyanushidullewe antiplatelettherapyadpreceptorantagonists
AT heptinstallstan antiplatelettherapyadpreceptorantagonists